Publications by authors named "Sharon Baughman"

Claim this Profile
A
Antibody-drug conjugate drug development: where are the challenges?
Laura Wright, Sharon Baughman, Ashleigh Wake

Bioanalysis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans.
George Atiee, Kenneth Lasseter, Sharon Baughman, Amy McCullough, Phil Collis

J Clin Pharmacol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations and requirements for the design of bioanalytical testing used in comparability studies for biosimilar drug development.
Xiao-Yan Cai, Dominique Gouty, Sharon Baughman, Ms Ramakrishnan, Constance Cullen

Bioanalysis· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys.
Andrew J S Jones, Damon I Papac, Edward H Chin, Rodney Keck, Sharon A Baughman

Glycobiology· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of a novel depot formulation of abarelix, a gonadotropin-releasing hormone (GnRH) antagonist, in healthy men ages 50 to 75.
Shekman L Wong, David T-W Lau, Sharon A Baughman, Nick Fotheringham, Dora Menchaca

J Clin Pharmacol· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of anakinra in subjects with different levels of renal function.
Bing-Bing Yang, Sharon Baughman, John T Sullivan

Clin Pharmacol Ther· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer.
Shekman L Wong, David T-W Lau, Sharon A Baughman, Dora Menchaca, Marc B Garnick

Clin Pharmacol Ther· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis